ANDA 75910, held by Actavis Elizabeth. Diclofenac Sodium.
As of Nov 16, 2026, ANDA 75910 (Diclofenac Sodium), held by Actavis Elizabeth, was first approved by FDA on Jan 7, 2002, with 8 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 7, 2002 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Diclofenac Sodium100MG · tablet, extended release;oral | Diclofenac Sodium | Discontinued |
| Nov 21, 2024 | Supplement 31Labeling · Standard review | Approved | None posted |
| Sep 12, 2024 | Supplement 30Labeling · Standard review | Approved | None posted |
| Apr 28, 2021 | Supplement 28Labeling · Standard review | Approved | None posted |
| Mar 29, 2021 | Supplement 25Labeling · Standard review | Approved | None posted |
| Oct 26, 2014 | Supplement 20Labeling | Approved | None posted |
| May 13, 2009 | Supplement 16Labeling | Approved | None posted |
| Jul 28, 2006 | Supplement 9Labeling | Approved | None posted |
| Jul 11, 2002 | Supplement 1Manufacturing | Approved | None posted |
| Jan 7, 2002 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters